Cargando…
Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
3,4-Methylenedioxymethamphetamine (MDMA) is currently being investigated as an adjunctive treatment to therapy for posttraumatic stress and other anxiety related disorders in clinical trials. Within the next few years MDMA-assisted therapy is projected for approval by regulatory authorities. MDMA’s...
Autores principales: | Makunts, Tigran, Dahill, Diane, Jerome, Lisa, de Boer, Alberdina, Abagyan, Ruben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233020/ https://www.ncbi.nlm.nih.gov/pubmed/37275981 http://dx.doi.org/10.3389/fpsyt.2023.1149766 |
Ejemplares similares
-
Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
por: Makunts, Tigran, et al.
Publicado: (2022) -
Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database
por: Cohen, Isaac V., et al.
Publicado: (2021) -
Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data
por: Joulfayan, Haroutyun, et al.
Publicado: (2023) -
Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events
por: Makunts, Tigran, et al.
Publicado: (2022) -
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports
por: Cohen, Isaac V., et al.
Publicado: (2020)